The putative role of leukotrienes in experimental atherogenesis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 1-2, 2009, Pages 90-94

  Jawień, Jacek ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

5 lipoxygenase activating protein (FLAP); Atherosclerosis; Leukotriene

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE; BAYX 1005; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MONTELUKAST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ROOT; ATHEROGENESIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; REVIEW; T LYMPHOCYTE;

EID: 61349157875     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.620     Document Type: Review

References (53)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695.
2. Jawień J, Nastałek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol. 2004; 55: 503-517.
3. Piedrahita JA, Zhang SH, Hagaman JR, et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA. 1992; 89: 4471-4475.
4. Plump AS, Smith JO, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E - deficient mice created by homologous recombination in ES cells. Cell. 1992; 71: 343-353.
5. Savla U. At the heart of atherosclerosis. Nat Med. 2002; 8: 1209.
6. Ishibashi S, Herz J, Maeda N, et al. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA. 1994; 91: 4431-4435.
7. Naksahima Y, Plump AS, Raines EW, et al. ApoE deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterio-scler Thromb. 1994; 14: 133-140.
8. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002; 91: 120-126.
9. Haeggstrom JZ, Samuelsson B. Overview of the 5-lipoxygenase pathway. In: Drazen JM, Dahlen SE, Lee TH, eds. Five-lipoxygenase products in asthma. Twon, Marcel Dekker, Inc.; 1998: 1-6.
10. Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci USA. 1979; 76: 3213-3217.
11. De Caterina R, Zampolli A. From asthma to atherosclerosis - 5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med. 2004; 350: 4-7.
12. Cyrus T, Witztum JL, Rader DJ, et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice. J Clin Invest. 1999; 103:1597-1604.
13. Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J Clin Invest. 1999; 103:1487-1488.
14. Cathcart MK, Folcik VA. Lipoxygenases and atherosclerosis: protection versus pathogenesis. Free Radic Biol Med. 2000; 28: 1726-1734.
15. Harats D, Shaish A, George J, et al. Overexpression of 15-lipooxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor - deficient mice. Arterioscler Thromb Vasc Biol. 2000; 20: 2100-2105.
16. Funk CD, Cyrus T. 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc Med. 2001; 11: 116-124.
17. George J, Afek A, Shaish A, et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001; 104: 1646-1650.
18. Cyrus T Pratico D, Zhao L, et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation. 2001; 103: 2277-2282.
19. Huo Y, Zhao L, Hyman MC, et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 110: 2024-2031.
20. Zhao L, Pratico D, Rader DJ, Funk CD. 12/15-lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat. 2005; 78: 185-193.
21. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-1243.
22. 4 production in human atherosclerotic plaques. Biomed Biochim Acta. 1988; 47: S182-185.
23. Radmark 0. 5-lipoxygenase-derived leukotrienes. Mediators also of atherosclerotic inflammation. Arterioscler Thromb Vasc Biol. 2003; 23: 1140-1142.
24. Kuhn H, Anton M, Gerth C, Habenicht A. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler Thromb Vasc Biol. 2003; 23: 1072-1076.
25. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med. 2004; 14: 191-195.
26. Zhao L, Moos MR Grabner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004; 10: 966-973.
27. Palinski W. Aneurysms: leukotrienes weaken aorta from the outside. Nat Med. 2004; 10: 896-898.
28. Kuhn H, Römisch I, Belkner J. The role of lipoxygenase-isoforms in atherogenesis. Mol Nutr Food Res. 2005; 49: 1014-1029.
29. Kuhn H. Biologic relevance of lipoxygenase isoforms in atherogenesis. Expert Rev Cardiovasc Ther. 2005; 3: 1099-1110.
30. Lȯtzer K, Funk CD, Habenicht AJ. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta. 2005; 1736: 30-37.
31. Bäck M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med. 2006; 38: 493-502.
32. Radmark 0, Samuelsson B. 5-lipoxygenase: regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat. 2007; 83: 162-174.
33. Vidal C, Gómez-Hernindez A, Sánchez-Galán E, et al. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther. 2007; 320: 108-116.
34. Spanbroek R, Habenicht AJ. The potential role of antileukothene drugs in atherosclerosis. Drug News Perspect. 2003; 16: 485-489.
35. Wickelgren I. Gene suggests asthma drugs may ease cardiovascular inflammation. Science. 2004; 303: 941.
36. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nature. 2005; 4: 664-672.
37. Bäck M. Leukotrienes: potential therapeutic targets in cardiovascular diseases. Bull Acad Natl Med. 2006; 190:1511-1518.
38. Mehrabian M, Allayee H. 5-lipoxygenase and atherosclerosis. Curr Opin Lipidol. 2003; 14: 447-457.
39. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004; 350: 29-37.
40. Aiello RJ, Bourassa PA, Lindsey S, et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc BioL 2002; 22: 443-449.
41. Lotzer K, Spanbroek R, Hildner M, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 2003; 23: e32-e36.
42. Helgadottir A, Manolescu A, Thorieifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004; 36: 233-239.
43. Jawień J, Gajda M, Rudling M, et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest. 2006; 36: 141-146.
44. Jawień J, Gajda M, Olszanecki R, Korbut R. BAY×1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007; 58: 583-538.
45. Jawień J, Gajda M, Wołkow PP, et al. The effect of montelukast on atherogenesis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2008; 59: 633-639.
46. Back M, Sultan A, Ovchinnikova 0, Hansson GK. 5-Lipoxygenase-Ac-tivating Protein. A potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res. 2007; 100: 946-949.
47. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E - knockout mice. Cardiovasc Res. 2003; 59: 234-240.
48. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004; 24: 369-375.
49. 1, in smooth muscle cell recruitment. Circulation. 2005; 112: 578-586.
50. Bäck M, Bu DX, Bränström R, et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA. 2005; 102; 17501-17506.
51. Cao RY, St Amand T, Gräbner R, et al. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in apoE deficient mice. Atherosclerosis. 2008, Aug 15 [Epub ahead of print],
52. Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA. 2006; 103: 8161-8166.
53. Jawleń J. New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn. 2008; 118:127-130.